Form 8-K - Current report:
SEC Accession No. 0001437749-22-001270
Filing Date
2022-01-20
Accepted
2022-01-20 08:15:17
Documents
18
Period of Report
2022-01-14
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20220118b_8k.htm   iXBRL 8-K 31023
2 EXHIBIT 99.1 ex_325573.htm EX-99.1 18236
3 EXHIBIT 99.2 ex_325799.htm EX-99.2 1827
8 letter01.jpg GRAPHIC 182268
9 letter02.jpg GRAPHIC 46136
10 logo01.jpg GRAPHIC 5424
  Complete submission text file 0001437749-22-001270.txt   513307

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nby-20220114.xsd EX-101.SCH 3586
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20220114_def.xml EX-101.DEF 11422
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20220114_lab.xml EX-101.LAB 15311
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20220114_pre.xml EX-101.PRE 11582
12 EXTRACTED XBRL INSTANCE DOCUMENT nby20220118b_8k_htm.xml XML 2565
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 22540719
SIC: 2834 Pharmaceutical Preparations